Table 1 Biochemical, demographic, clinical, and dosimetric characteristics of the patients at baseline and the person-months of follow-up

Baseline liver function score before radiotherapy

Bilirubin (BIL)

 0

90 (67.6)

1285.2

 1

17 (12.8)

217.0

 2

21 (15.8)

117.4

 3

4 (3.0)

5.6

 4

1 (0.8)

1.8

Aspartate aminotransferase (AST)

 0

28 (21.0)

574.6

 1

83 (62.4)

897.0

 2

14 (10.5)

124.9

 3

6 (4.5)

15.4

 4

1 (0.8)

12.8

 Missing

1 (0.8)

2.3

Alanine aminotransferase (ALT)

 0

59 (44.4)

788.4

 1

65 (48.8)

734.0

 2

8 (6.0)

91.8

 3

1 (0.8)

12.8

 4

0 (0.0)

0

Alkaline phosphatase (ALKP)

 0

59 (44.3)

983.7

 1

45 (33.8)

324.5

 2

15 (11.3)

75.0

 3

1 (0.8)

14.9

 4

0 (0.0)

0

 Missing

13 (9.8)

228.9

International normalized ratio (INR)

 0

103 (77.4)

1404.3

 1

17 (12.8)

110.7

 2

2 (1.5)

7.3

 3

0 (0.0)

0

 Missing

11 (8.3)

104.7

Albumin (ALB)

 0

53 (39.8)

803.8

 1

38 (28.6)

450.2

 2

28 (21.1)

196.0

 3

0 (0.0)

0

 missing

14 (10.5)

177.0

Age

  ≤ 60

35 (26.3)

446.1

  > 60–68

32 (24.1)

353.9

  > 68–76

35 (26.3)

538.0

  > 76

31 (23.3)

289.0

Gender

 Female

34 (25.6)

422.6

 Male

99 (74.4)

1204.4

Portal vein tumor thrombosis (PVTT)/Inferior vena cava tumor thrombosis (IVCTT)

 Positive

100 (75.2)

1049.7

 Negative

33 (24.8)

577.3

Hepatitis B virus (HBV)

 Positive

75 (56.3)

814.5

 Negative

55 (41.4)

724.3

 Missing

3 (2.3)

88.2

Hepatitis C virus (HCV)

 Positive

40 (30.1)

627.6

 Negative

90 (67.6)

911.2

 Missing

3 (2.3)

88.2

Dosimetric factors of radiotherapy

Clinical target volume (CTV)—mL

 Mean (SD)

298.5 (415.4)

–

 Median (range)

147.6 (7.9 – 3316.7)

–

Normal liver volume (NLV)—mL

 Mean (SD)

1365.2 (638.5)

–

 Median (range)

1216.9 (493.6 – 5517.6)

–

Normal liver mean dose (NLD_mean)—Gy

 Mean (SD)

17.7 (4.8)

–

 Median (range)

18.0 (2.2 – 29.7)

–

 Total

133

1627.0